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Abstract
Background: The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical malaria for at
least 21 months in a trial in Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or
clinical malaria; however the underlying mechanisms that determine efficacy and its duration remain unknown. We
performed a new, exploratory analysis to explore differences in the duration of protection among participants to better
understand the protection afforded by RTS,S.
Methodology/Principal Findings: The study was a Phase IIb double-blind, randomized controlled trial in 2022 children aged
1 to 4 years. The trial was designed with two cohorts to estimate vaccine efficacy against two different endpoints: clinical
malaria (cohort 1) and infection (cohort 2). Participants were randomly allocated to receive three doses of RTS,S/AS02A or
control vaccines. We did a retrospective, unplanned sub-analysis of cohort 2 data using information collected for safety
through the health facility-based passive case detection system. Vaccine efficacy against clinical malaria was estimated over
the first six-month surveillance period (double-blind phase) and over the following 12 months (single-blind phase), and
analysis was per-protocol. Adjusted vaccine efficacy against first clinical malaria episodes in cohort 2 was of 35.4% (95% CI
4.5–56.3; p=0.029) over the double-blind phase and of 9.0% (230.6–36.6; p=0.609) during the single-blind phase.
Conclusions/Significance: Contrary to observations in cohort 1, where efficacy against clinical malaria did not wane over
time, in cohort 2 the efficacy decreases with time. We hypothesize that this reduced duration of protection is a result of the
early diagnosis and treatment of infections in cohort 2 participants, preventing sufficient exposure to asexual-stage
antigens. On the other hand, the long-term protection against clinical disease observed in cohort 1 may be a consequence
of a prolonged exposure to low-dose blood-stage asexual parasitaemia.
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Introduction
Developing a new vaccine is a long and complex process. For
example, RTS,S/AS (GSK, Rixensart, Belgium), a pre-erythro-
cytic vaccine based on Plasmodium falciparum circumsporozoite
surface protein (CSP) and the candidate malaria vaccine in the
most advanced development phase, has been in development for
more than two decades. After having demonstrated partial
protection against infection in non-immune and semi-immune
adults [1–3], it underwent proof-of-concept trials in children and
infants in Mozambique [4,5], that were then followed by trials in
Kenya and Tanzania [6,7] prior to the planned launch of wider
Phase III efficacy trials.
One of the most critical decisions when preparing a vaccine’s
clinical development plan is the proper selection of criteria by
which the product will be advanced, re-engineered or terminated.
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5165Selection of appropriate study endpoints in the various trials that
lead up to definitive Phase III efficacy studies is an important part
of this process. Different endpoints can be used to estimate efficacy
of a pre-erythrocytic vaccine: P. falciparum asexual-stage infection,
clinical malaria, severe malaria or death. Selection of the endpoint
depends on several factors, including the type of vaccine, the phase
of the trial and the evidence needed for advocacy and policy
decision, and it will determine the sample size and have
implications in terms of cost and time. Infection is the endpoint
closest to the biological target of the vaccine and is influenced by
fewer local cofactors, such as management of malaria cases and
parasite and human genetics. As we go downstream (endpoints
such as severe malaria or total mortality), the clinical and public
health relevance increases, providing stronger evidence for
advocacy and policy decision, but the number of cofactors
influencing the risk of malaria is larger, potentially decreasing
the generalizability of results [8,9].
In 2003, a randomized controlled Phase IIb proof-of-concept
trial was conducted in Mozambique to provide a preliminary
estimate of the efficacy, immunogenicity and safety of RTS,S/
AS02A malaria vaccine in an age group (1 to 4 years) that would
be close to the ultimate target population (infants) [4,10]. The trial
was designed with two cohorts so that it would be possible to
estimate vaccine efficacy against two different endpoints: infection
and clinical malaria. Cohort 1 was designed to examine efficacy
against clinical malaria, because estimation of vaccine efficacy for
an endpoint with public health relevance was sought, assessed
through health facility-based passive case detection (PCD). During
the first six months of follow up (double-blind phase) the vaccine
efficacy for the time to first or only clinical malaria episode was
29.9% (95% CI 11.0–44.8; p=0.004). As an exploratory analysis
efficacy against severe malaria was also assessed in this cohort,
with an estimate of 57.7% (16.2–80.6; p=0.019). Anti-CSP
antibodies measured one month after the third vaccine dose were
not correlated with the risk of clinical malaria. Cohort 2 enrolled a
separate group of children who lived in an area with higher
transmission intensity and who contributed to the assessment of
the efficacy for time to first asexual-stage P. falciparum parasitaemia
infection. By enrolling this second cohort it was possible to
estimate efficacy for a more upstream endpoint and to evaluate
how it correlated with efficacy against clinical malaria in Cohort 1.
Participants in Cohort 2 were followed up through both active
detection of infection (ADI) and PCD. During the double-blind
phase the vaccine efficacy for time to first infection was 45.0%
(31.4–55.9; p,0.0001) [4].
After unblinding data of the first six months of follow up,
participants were followed up for an additional 12 months (single-
blind phase), during which vaccine efficacy for the first or only
clinicalmalariaepisodeincohort1was28.9%(8.4–44.8;p=0.008).
Therefore the vaccine efficacy did not wane, showing sustained
protection during at least 18 months [10]. In cohort 2 almost all
children had already had a P. falciparum infection during the double-
blind phase,thereforeitwas not possibletocontinuetheADI during
the single-blind phase, in which children were only followed up for
safety surveillance through health facility-based PCD.
The correlation between efficacy against clinical malaria in
cohort 1 and efficacy against infection in cohort 2 showed that
infection could be used as the primary endpoint for efficacy trials
of pre-erythrocytic vaccines, which allows conducting smaller trials
with high power, decreasing time and cost. Based on these results,
a Phase I/IIb randomized controlled trial was recently conducted
in infants in the same area to assess the safety, immunogenicity
and efficacy of RTS,S/AS02D malaria vaccine, administered at
10, 14 and 18 weeks of age, staggered with the Expanded Program
on Immunization vaccines [5]. This infant trial was designed with
a single cohort, which was followed up through ADI and PCD,
using the same design as for cohort 2 of the previous trial. First or
only infection was the main endpoint for evaluation of vaccine
efficacy, but further analyses of vaccine efficacy against clinical
malaria were explored. During the first three months of follow up,
the efficacy against first infection was 65.9% (42.6–79.8;
p,0.0001) and that for first or only clinical episode of malaria
was 65.8% (25.3–84.4; p=0.007). In this study in young infants
anti-CSP antibodies one month after the third vaccine dose were
strongly associated with a reduction in the risk of infection [5].
In these two trials vaccine efficacy estimates vary for different
endpoints, transmission intensities and age groups. To provide
more evidence on the factors that may influence vaccine response
and its duration, we performed a sub-analysis of cohort 2 data
from the study in children, that was not included in the original
protocol, to estimate vaccine efficacy for clinical malaria in this
cohort, using information collected for safety through the health
facility-based PCD system.
Results
417 children were recruited and randomized in cohort 2 (209
received dose one of the RTS,S/AS02A vaccine and 208 received
dose one of the control vaccines). Details of the trial profile, the
baseline characteristics, the safety, reactogenicity, part of the
immunogenicity data and the efficacy against infection in cohort 2
have been previously reported [4,10].
Efficacy during the double-blind phase (study months
2.5–8.5) of the ATP cohort
In the analysis of the according-to-protocol (ATP) cohort over
the double-blind phase (study months 2.5–8.5), 102 children had a
first episode of clinical malaria (primary case definition) (46 per
72.8 person-years at risk (PYAR) in the RTS,S/AS02A group and
56 per 59.3 PYAR in the control group), giving a crude vaccine
efficacy for the time to first or only clinical malaria episode of
34.3% (95% CI 3.0–55.6; p=0.035) and an adjusted efficacy of
35.4% (95% CI 4.5–56.3; p=0.029, Table 1). Figure 1 presents
the Kaplan-Meier survival curves for the cumulative proportion
with at least one episode of clinical malaria in cohort 2. A test for
proportionality of hazards showed that these were not constant
over time (Schoenfeld residuals p=0.004), therefore suggesting
waning efficacy over the double-blind phase.
A more detailed analysis of clinical cases occurring in the double-
blind phase revealed that 15 children had more than one malaria
episode during the double-blind phase (6 in the RTS,S/AS02A
group and 9 in the control group) and the adjusted vaccine efficacy
for multiple malaria episodes was 30.0% (21.8–51.9; p=0.062).
The primary case definition (fever and parasitaemia .2500/
mL), that was chosen for cohort 1 based on baseline data from
Manhic ¸a, was estimated to be 97.4% sensitive (95% CI 88.8–
100.0) and 72.3% specific (49.3–83.6) for cohort 2. Vaccine
efficacies using other more specific case definitions are presented
in Table 1. The case definitions using fever and parasitaemia
.15000 parasites/mLo r.50000 parasites/mL had a sensitivity of
82.3% (60.0–98.0) and 60.0% (33.0–85.5) and a specificity of
83.7% (72.1–92.3) and 92.3% (83.7–97.1) respectively.
Efficacy during the single-blind phase (study months 8.5–
21) of the ATP cohort
During the single-blind phase (study months 8.5–21) 119
children of the ATP cohort had a first or only episode of clinical
malaria, yielding a crude vaccine efficacy of 6.4% (95% CI
RTS,S-Induced Protection
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36.6; p=0.609). Figure 2 presents the Kaplan-Meier survival
curves for the cumulative proportion with at least one episode of
clinical malaria in cohort 2.
Efficacy during the first 3.5 months of the double-blind
phase (study months 2.5–6) of the ATP cohort
To be able to compare the vaccine efficacy during the same
follow up time period in cohort 2 to that in the infant trial
conducted recently in the same area, an analysis was also done for
a shorter follow up period of 3.5 months (study months 2.5–6).
During this period 111 children in the RTS,S/AS02A group and
147 children in the control group had first episodes of asexual P.
falciparum parasitaemia, giving an adjusted vaccine efficacy against
first infection of 51.1% (37.3–61.9; p,0.0001). Twenty-one
children in the RTS,S/AS02A group and 40 children in the
control group had a first episode of clinical malaria (primary case
definition), yielding an adjusted efficacy for clinical malaria of
61.0% (33.7–77.0; p=0.0005).
During the double-blind phase the geometric mean density of
asexual-stage parasites at the first or only infection was significantly
lower in asymptomatic children (1810 parasites/mL) than in
children who presented fever (28314 parasites/mL; p,0.0001).
Efficacy of the ITT cohort
In the analysis of the intention-to-treat (ITT) cohort over the
double-blind phase, 148 children had a first episode of clinical
Figure 1. Kaplan-Meier survival curves for the cumulative proportion with at least one episode of clinical malaria during the
double-blind and single-blind phases in cohort 2 respectively (ATP cohort).
doi:10.1371/journal.pone.0005165.g001
Table 1. Vaccine efficacy against clinical malaria in cohort 2 (ATP cohort).
Endpoint and follow up period Control vaccine RTS,S/AS02A
Vaccine efficacy*
(95% CI) p
#
Events PYAR
1 Rate Events PYAR
1 Rate
Double-blind phase (study months 2.5–8.5)
First or only episode of fever and parasitaemia .2500/mL 56 59.3 0.94 46 72.8 0.63 35.4% (4.5; 56.3) 0.029
First or only episode of fever and parasitaemia .15 000/mL 47 61.1 0.77 41 73.8 0.56 30.5% (25.7; 54.4) 0.089
First or only episode of fever and parasitaemia .50 000/mL 33 64.4 0.51 23 76.4 0.30 42.7% (2.2; 66.4) 0.041
Multiple episodes of fever and parasitaemia .2500/mL 68 70.32 0.97 52 79.2 0.66 30.0% (21.8; 51.9) 0.062
Single-blind phase (study months 8.5–21)
First or only episode of fever and parasitaemia .2500/mL 59 115.4 0.51 60 123.1 0.49 9.0% (230.6; 36.6) 0.609
1Person-years at risk.
#p-value from Cox regression model using Wald test.
*Treatment effect adjusted by: Age at dose 1, Bednet use at baseline, Distance to health centre (Km).
doi:10.1371/journal.pone.0005165.t001
RTS,S-Induced Protection
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group), with a crude estimate of vaccine efficacy against clinical
malaria of 9.3% (225.3–34.3; p=0.555). The corresponding
estimate during the single-blind phase was of 24.2% (132 children
had a first episode of clinical malaria, 246.6–25.9%; p=0.813).
Relation between malaria protection and anti-CSP
antibodies
The relation between anti-CSP antibody titers and the risk of
infection and clinical malaria during the double-blind phase was
evaluated. The hazard ratio for first or only infection per ten-fold
increase in the value of anti-CSP IgG was 0.41 (95% CI 0.28–
0.60; p,0.0001). When comparing children in the higher tertile
against those in the lower tertile value of anti-CSP IgG, the hazard
ratio was 0.54 (0.37–0.79; p=0.002). The equivalent hazard ratios
for first or only episode of clinical malaria were 0.99 (0.50–1.94;
p=0.966) and 0.90 (0.44–1.86; p=0.780) respectively. Thus anti-
CSP antibody levels correlated with protection against infection
but not with protection against clinical malaria episodes.
Discussion
In cohort 2, adjusted efficacy of the RTS,S/AS02A candidate
malaria vaccine against first or only clinical malaria episodes in
Mozambican children aged 1 to 4 years was of 35.4% during the
first six months of follow up (ATP cohort), decreasing to 9.0% in
the subsequent 12 months of follow up. The follow up of cohort 2
participants, which included both ADI and PCD, was designed to
estimate vaccine efficacy against new P. falciparum infections.
Consequently the sample size for this cohort, based on this
endpoint, was much smaller than for cohort 1. Nevertheless, a
high incidence of clinical malaria episodes also allowed estimating
vaccine efficacy against this endpoint, although with a lower
precision.
The primary case definition used (fever and a parasitaemia
.2500 parasites/mL) was chosen for cohort 1 based on previous
background data from the Manhic ¸a area, where it had been
estimated to be 91% specific and 95% sensitive [11]. Using the
actual data from cohort 1 this case definition was 95% specific and
86% sensitive (data not shown). This definition had a lower
specificity in cohort 2 (72.3%), as malaria transmission in Ilha
Josina is higher and children were more immune. Using definitions
with higher specificities (fever and parasitaemia .50.000/mL)
yielded higher vaccine efficacy estimates (42.7%) [12], similar to
the efficacy against first or only infection (45.0% (31.4–55.9;
p,0.0001)), assessed for the double-blind phase [4].
Efficacy estimates for clinical malaria in cohort 2 are much
lower in the ITT analysis, starting at dose 1 and including the
vaccination period, than in the ATP analysis, starting post dose 3.
In the ITT analysis time at risk is larger and there are smaller
differences in the number of clinical episodes between the RTS,S/
AS02A and control group during these first 2.5 months, possibly
due to the administration of anti-malarial treatment before dose 3
and that children have not yet received the three vaccine doses,
decreasing the differences between the total incidences of the
double-blind phase. During the following months, maybe due to
the children who have not completed the three doses vaccination
course, there is a smaller difference in the number of malaria cases
between the RTS,S/AS02A and control group compared to the
ATP cohort, thus decreasing the vaccine efficacy.
Data show that cohort 2 children that received RTS,S/AS02A
were partially protected against infection and clinical disease in the
first six months of follow up post dose 3 (35.4%), at levels similar to
cohort 1 (29.9% (95% CI 11.0–44.8; p=0.004)) [4]. However,
thereafter the efficacy against clinical malaria wanes (the
evaluation of the proportionality of the hazard assumption reveals
that the efficacy in cohort 2 changes with time) and there was no
difference in the risk of malaria between RTS,S/AS02A and
Figure 2. Kaplan-Meier survival curves for the cumulative proportion with at least one episode of clinical malaria during the
double-blind and single-blind phases in cohort 2 respectively (ATP cohort).
doi:10.1371/journal.pone.0005165.g002
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contrast to study participants in cohort 1, where vaccine efficacy
remained stable, with no evidence of waning for at least 21 months
(35.3% (95% CI 21.6–46.6; p,0.0001)) [10].
What are the main differences between cohort 1 and cohort 2
that might explain the discrepancy in vaccine duration of
protection? Firstly, the different study design and follow up of
participants. In cohort 1 no antimalarial treatment was given to
clear parasitaemia before dose 3 and only health facility-based
PCD was conducted to detect malaria cases. Therefore those
children who became infected with P. falciparum had, on average,
longer periods of low density parasitaemia, as they were only
treated when parasite density reached the fever threshold and the
child was taken to the health facility for diagnosis and treatment.
Geometric mean parasitaemias (GMPs) at the time of presentation
with a clinical malaria episode in cohort 1 were 43522 for the
RTS,S/AS02A and 41867 parasites/mL for the control group [4].
On the other hand, in cohort 2 antimalarials were given two weeks
before dose 3 and ADI was conducted for six months, during
which all children with parasitaemia were treated irrespective of
symptoms, their immune system not being exposed to low-density
asymptomatic parasitaemias for very long. In cohort 2 the GMPs
were similar (3950 parasites/mL in the control group and 3016 in
the RTS,S/AS02A group, p=0.354) at first infection and
treatment [4], but significantly lower in those that were
asymptomatic than in those with fever (1810 vs. 28314
parasites/mL).
Secondly, the malaria transmission intensity was higher in Ilha
Josina, the area where cohort 2 was recruited, as reflected by the
geometric mean of antibodies against the whole parasite measured
by indirect fluorescent antibody test (IFAT) and the percentage of
splenomegaly at baseline. Therefore participants in Cohort 2 may
have had a higher level of naturally acquired immunity against
infection and clinical malaria when the trial started.
To understand the effect of vaccination and duration of
protection, it is difficult to disentangle the effects of the study
design from other potential factors such as the immunity level at
the time of vaccination and the malaria exposure. RTS,S has
shown to extend time to first infection, as seen in cohort 2, which
results in reduced risk of clinical malaria, as seen in cohort 1 and 2
during the first 6 months of follow up. In cohort 1 sustained
protection was shown for at least 21 months, and this must be a
function of either sustained pre-erythrocytic immunity or induc-
tion of asexual-stage immunity. Moreover, waning efficacy in
cohort 2 can be interpreted as waning pre-erythrocytic immunity.
However, similar anti-CSP antibody levels between cohort 1 and 2
(data not shown) would argue against differential pre-erythrocytic
immunity explaining the differences in the duration of protection.
Based on this line of reasoning, we hypothesize that, as the
vaccine-induced pre-erythrocytic immunity declines following the
peak levels achieved after vaccination, it only partially inhibits
hepatocyte invasion, liver-stage development and release of
merozoites to the blood, decreasing the parasite load in the face
of a new infection. A low-dose parasitaemia resulting from the
partial pre-erythrocytic immunity might be critical to induce or
boost the development of asexual blood-stage immune responses,
which may confer long-lasting protection against clinical malaria.
This low-dose parasitaemia has to be maintained for enough time
to stimulate the asexual-stage immune response. Therefore the
short-lived vaccine-induced pre-erythrocytic response facilitates
the development of a long-lasting asexual-stage immunity in the
presence of new infections that act as natural asexual-stage
boosters. A vaccine inducing partial pre-erythrocytic protection,
like RTS,S/AS, might allow the development of a better and more
sustained asexual-stage protection than a more efficacious vaccine,
by allowing this ‘‘leakage’’ of low-dose parasites.
This is consistent with other recent hypotheses [13] and
observations in studies that assessed the capacity of low
parasitaemias to induce or maintain protective immune responses
[14–17]. Similar mechanisms have also been proposed to explain
the sustained protection of intermittent preventive treatment with
sulfadoxine-pyrimethamine administered in infancy (IPTi) in
Tanzanian children [18].
Children in cohort 1 were probably exposed to low-density
parasitaemias for a longer time than children in cohort 2, in which
the development of this enhanced asexual-stage immune response
may have been impaired. We propose this may explain a waning
of the vaccine-specific protective response in cohort 2.
The short duration of protection in cohort 2 is not surprising
and is similar to that observed in other RTS,S trials [1,3] or
irradiated sporozoites trials [19]. Despite differences in the age of
participants and endemicity of malaria, results were comparable to
those of cohort 2 in Mozambique. Furthermore, during the first
three months of follow up after the third vaccine dose the efficacy
of RTS,S was between 40 and 70% for all trials (infants [5], cohort
1 (data not shown) and cohort 2 of children aged 1 to 4 years, and
adults [1]), irrespective of age or transmission intensity, when using
a highly specific malaria case definition. The initial response to the
RTS,S/AS02 does not seem to vary in the different trials, what
appears to change is the ability to induce a long-lasting protective
response.
With regard to antibody responses to the vaccine in cohort 2
children, the level of anti-CSP IgG was correlated with a lower risk
of infection but not with a lower risk of clinical malaria. In cohort
1 it had not been correlated with the risk of clinical malaria either
[4] and in the infant trial it had also been correlated with a lower
risk of infection [5]. In addition, antibody levels decayed over the
double-blind phase, but remained at the end of the single-blind
phase at levels 40 fold higher than in controls [10]. This indicates
that anti-CSP antibodies, probably together with other cellular
immune responses, may be involved in the initial protection and
are correlated with protection against infection, supporting the
above-mentioned hypothesis. Nevertheless, other unknown im-
mune mechanisms, most likely involving priming of asexual-stage
humoral and cellular immunity, developed as the pre-erythrocytic
immunity decays, may be responsible for the long-lasting
protection against disease. This points towards the need to assess
antibody and cellular asexual-stage immune responses in future
Phase III RTS,S/AS vaccine trials.
When designing future pre-erythrocytic malaria vaccine trials it
has to be taken into account that the study design might have a
great impact on the duration of protection. ADI with rapid
treatment of parasitaemias might impair the development of long-
lasting protection, although initial efficacy seems to be indepen-
dent of study design, age or malaria transmission intensity. If
assessment of duration of protection is included in the trial
objectives the design should consist only of a PCD follow up.
Otherwise, if the main aim is to obtain quick efficacy results, a
smaller trial with P. falciparum infection as the primary endpoint
and ADI can be used.
In conclusion, the preponderance of data discussed leads to the
following hypothesis: that the long-term protection against clinical
disease observed in RTS,S/AS02A recipients is a consequence of a
partially protective vaccine-induced pre-erythrocytic response that
lasts several months, and limits the number of viable sporozoites
and merozoites emerging from the liver to initiate the blood stage
cycle of the infection. This leads to prolonged exposure to low-
dose asexual blood-stage parasites that allows the acquisition of
RTS,S-Induced Protection
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include prompt ascertainment and treatment of infections in the
absence of symptoms may modify long-term protection. Vaccina-
tion in infancy therefore has the potential to confer important
levels of protection through a time of high susceptibility in early
childhood. A fuller understanding of the mechanism of vaccine
action including determination of the efficacy and duration under
varying conditions of malaria transmission will be reached through
the conduct of properly designed Phase III trials.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
The trial was conducted at the Centro de Investigac ¸a ˜o em
Sau ´de da Manhic ¸a (CISM, Manhic ¸a Health Research Centre), in
Manhic ¸a District (Maputo Province), southern Mozambique. The
area is under demographic surveillance system (DSS) and has been
described in detail elsewhere [20]. Adjacent to CISM is the
Manhic ¸a District Hospital (110 beds), the main referral hospital in
the area. The climate is subtropical with a rainy season from
November to April and a cool and dry season during the rest of the
year. Malaria transmission, mainly caused by P. falciparum,i s
perennial with marked seasonality. The trial was conducted in two
different areas: Manhic ¸a and Maragra, where cohort 1 (n=1605)
was recruited, and Ilha Josina, 55 km north of Manhic ¸a, where
cohort 2 (n=417) was recruited. The estimated entomological
inoculation rate for the Manhic ¸a area in 2002 was 38 infective
bites/person/year, being Anopheles funestus the main vector. In Ilha
Josina the transmission is higher than in Manhic ¸a, as reflected by a
significantly higher geometric mean of antibodies against the
whole parasite as assessed by IFAT and percentage of spleno-
megaly at baseline in study participants recruited in that area [4].
The study was a Phase IIb double-blind, randomized controlled
trial in children aged 1 to 4 years to assess the efficacy,
immunogenicity and safety of RTS,S/AS02A candidate malaria
vaccine according to a 0, 1, 2 month vaccination schedule [4].
The study design has been described in detail elsewhere [4,10].
This paper presents a retrospective, unplanned sub-analysis of
cohort 2 data. According to protocol, the surveillance period
started 14 days after dose 3. Participants were followed for six
months during the double-blind phase (study months 2.5–8.5),
after which data were unblinded and analyzed, and were then
followed up for 12 additional months during the single-blind phase
(study months 8.5–21). Figure 3 presents the study design and
follow up phases.
In the original protocol, the efficacy endpoint in cohort 2,
assessed during the double-blind phase, was first P. falciparum
infection, as detected by ADI or health facility-based PCD.
According to protocol, information on clinical malaria episodes of
cohort 2 participants was collected through PCD throughout the
double and single-blind phases, with the objective of using these
data for monitoring safety rather than the formal evaluation of
vaccine efficacy. The rationale for that was that interpretation of
efficacy results of clinical malaria disease collected at health centers
would be compromised by the ADI visits and the sample size would
be inadequate. However, despite the limitations of the study design
and sample size, to gain further insights into the mechanism of long
lasting protection, we have now performed an exploratory analysis,
using these data to estimate incidence of clinical malaria and
vaccine efficacy against clinical malaria in cohort 2.
The protocol was approved by the National Mozambican Ethics
Review Committee, the Hospital Clı ´nic of Barcelona Ethics
Review Committee and the PATH Human Subjects Protection
Committee. The trial was conducted according to the Interna-
tional Conference on Harmonisation good clinical practice
guidelines, and was monitored by GSK Biologicals. A local safety
monitor and a data and safety monitoring board closely reviewed
the conduct, safety and data of the trial.
Figure 3. Study design.
doi:10.1371/journal.pone.0005165.g003
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Procedures
Screening, informed consent, enrolment, randomization, im-
munization and safety assessment were done as previously
described [4,10]. Participants were randomized to receive three
doses of either RTS,S/AS02A candidate malaria vaccine or a
control vaccine. RTS,S is a pre-erythrocytic vaccine based on P.
falciparum CSP, that is fused to the S antigen of the hepatitis B
virus, and is formulated with the AS02A Proprietary Adjuvant
System. Details of the formulation and dosing of the vaccine have
been reported elsewhere [4]. The control vaccines for children
younger than 24 months were two doses of the seven-valent
pneumococcal conjugate vaccine (Prevenar
TM Wyeth Lederle
Vaccines) and one dose of Haemophilus influenzae type b vaccine
(GSK Biologicals) and for children aged $24 months the pediatric
hepatitis B vaccine (GSK Biologicals).
A round-the-clock health facility-based morbidity surveillance
system was operating at the Manhic ¸a District Hospital and the
Maragra and Ilha Josina health posts throughout the study. A
standardized questionnaire form, which includes personal and
demographic data and clinical signs and symptoms, was completed
for each child seen at the outpatient clinic. The axillary
temperature was measured with an electronic thermometer and
recorded and a finger-prick blood sample was collected from all
children who present fever (axillary temperature $37.5uC) or
report a history of fever in the preceding 24 hours. Blood was
collected into heparinized capillaries to measure the packed cell
volume (PCV) and thin and thick blood smears were prepared to
determine parasitaemia. The first line malaria treatment for non
complicated malaria at the time of the study was sulfadoxine-
pyrimethamine and amodiaquine and the second-line treatment
was CoartemH (artemether-lumefantrine) (Novartis).
In cohort 2 participants were followed up by a combination of
ADI and PCD during the double-blind phase. Antimalarials (a
single oral dose of sulfadoxine 25 mg/kg plus pyrimethamine
1.25 mg/kg and amodiaquine 10 mg/kg for 3 days) were
administered to all participants 14 days before dose 3 to
presumptively clear parasites. Parasitaemia was checked two
weeks later and, if positive, the child was treated with the second
line antimalarial treatment and was not included in the assessment
for ADI. Surveillance for malaria infection was started 14 days
after dose 3 and was done throughout the double-blind phase
(study months 2.5–8.5) through ADI visits performed every two
weeks for 2.5 months and monthly for the following two months.
During the ADI a field worker visited participants at home,
completed a brief morbidity questionnaire and measured the
axillary temperature. If the child was afebrile the field worker
collected blood by fingerprick onto slides and filter paper. If the
child had fever or a history of fever in the preceding 24 hours, the
field worker accompanied the child to the Ilha Josina health post,
where he or she was examined and blood slides and filter paper
were collected. All children with P. falciparum parasitaemia received
antimalarial treatment, irrespective of symptoms, and were
excluded from subsequent ADI visits.
Antibodies against CSP were measured before dose one and 30
days after dose three and IFAT and spleen size (Hackett’s scale)
were measured at screening.
Laboratory methods
Blood slides were Giemsa-stained and read following standard
quality-controlled procedures [21]. External validation was done
at the Hospital Clı ´nic of Barcelona, Spain. The PCV was
measured using a microhematocrit centrifuge and a Hawksley
reader (Hawksley & Sons Ltd, Lancing, UK).
IgG antibodies specific for the CSP tandem repeat epitope were
measured by a standard ELISA with plates adsorbed with the
recombinant antigen R32LR that contains the sequence
[NVDP(NANP)15]2LR, using a standard serum as reference
[22]. For the IFAT, 25 mL of test sera (two-fold serial dilutions up
to 1/81920) were incubated with P. falciparum-infected red blood
cells fixed onto a 12-well slide. Positive reactions were revealed
with fluorescein isothiocyanate-labelled secondary antibody dilut-
ed in Evans blue. The highest dilution giving positive fluorescence
under an ultraviolet light microscope was scored.
Statistical methods and case definitions
Trial results presented previously [4,10] were analyzed
following a report and analysis plan established before unblinding.
The results presented here are exploratory analyses of cohort 2
that were not described in the protocol, performed on data
collected to 21 months post-study start. The endpoint of this sub-
analysis was first or only clinical episode of P. falciparum malaria. A
clinical episode was defined as a child with an axillary temperature
of $37.5uC and a P. falciparum asexual parasitaemia of .2500
parasites/mL on the blood slide (primary case definition), detected
through the health-facility based PCD or the ADI visits. Analyses
were performed on the ATP cohort, which was defined as children
who met all eligibility criteria, received the complete vaccination
course and contributed to the efficacy surveillance. Time at risk
started 14 days after dose 3 and the analysis was conducted for the
time periods 2.5 to 8.5 (double-blind phase) and 8.5 to 21 (single-
blind phase) study months. For data pertaining to the period 2.5 to
8.5 vaccine efficacy for other definitions of clinical malaria using
different cut-offs for parasitaemia and assessment of vaccine
efficacy for multiple malaria episodes was also calculated.
Absences from the study area of two or more weeks and a time
interval after antimalarial drug use (28 days after sulfadoxine-
pyrimethamine, 7 days after chloroquine alone, 7 days after
quinine alone, 7 days after amodiaquine and 20 days after
artemether+lumefantrine) were not included in the time at risk. If
the combination of drugs was given, the longest period was used.
For the analysis of multiple episodes of clinical malaria, we did not
judge a child to be susceptible for 28 days after the previous
episode. Vaccine efficacy for the time to first or only clinical
malaria episode was assessed using Cox regression models and
defined as (12Hazard Ratio). Vaccine efficacy was adjusted for
the covariates: age at dose 1, bednet use at baseline and distance
from the health centre (as determined by geopositioning of every
household with a handheld global positioning system with
differential correction). The interaction between age and vaccine
efficacy was not significant for any of the follow up periods, so an
interaction term was not included. The proportional hazards
assumption was investigated graphically, using a test based on the
Schoenfeld residuals [23] and time-dependent Cox models [24]
using interactions between the vaccine effect and one-degree
fractional polynomials of the time.
For multiple episodes of clinical malaria the vaccine effect was
assessed using Poisson regression models with normal random
intercepts, including the time at risk as an offset variable. Vaccine
efficacy was defined as (12Rate Ratio). The difference in the
geometric mean of the positive densities was assessed with the non-
parametric Wilcoxon test.
The sensitivity and specificity of different case definitions were
estimated for cohort 2 participants using data from the study
month 8.5 visit, following the methodology described by Smith
and colleagues [25].
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received at least one vaccine dose were included and efficacy
estimates were not adjusted for covariates. Time at risk started
from dose 1 and was not adjusted for absences from the study area
or antimalarial drug use.
The relation between anti-CSP antibody titers as measured 30
days post dose 3 and the risk of infection and clinical malaria was
assessed in RTS,S/AS02A recipients. The hazard ratio of
participants with anti-CSP antibodies in the higher tertile against
those in the lower tertile was estimated, as well as the hazard ratio
per ten-fold increase in the value of anti-CSP antibodies, using
Cox regression models.
The sample size of cohort 2 was calculated at the beginning of
the study to estimate vaccine efficacy against first or only infection
in cohort 2, which has been previously reported [4]. Based on the
incidence of clinical malaria in the control group of cohort 2 (0.94
episodes per PYAR during the double-blind phase and 0.51 during
the single-blind phase), the power to detect a vaccine efficacy
against clinical malaria of 40% or higher at a 5% significance level
during the first six months of follow up (double-blind phase) is of
65.8% and during the following 12 months (single-blind phase) is
of 68.0%.
Analyses were done using STATA version 10.0 (College
Station, TX, USA).
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